{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:35Z","timestamp":1790687495712,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.pharmthera.2013.11.001","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T22:45:16Z","timestamp":1384037116000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":299,"title":["An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies"],"prefix":"10.1016","volume":"141","author":[{"given":"Domenica","family":"Musumeci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni N.","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Montesarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.11.001_bb0005","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0010","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1189\/jlb.72.6.1084","article-title":"HMGB1 as a DNA-binding cytokine","volume":"72","author":"Andersson","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbagrm.2009.11.003","article-title":"The role of HMGB1 in the pathogenesis of rheumatic disease","volume":"1799","author":"Andersson","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/01.CCM.0000259534.68873.2A","article-title":"Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis","volume":"35","author":"Angus","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0030","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-12-0221","article-title":"S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis","volume":"18","author":"Arumugam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0035","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1097\/00003246-199310001-00003","article-title":"Tumor necrosis factor in the pathogenesis of infectious diseases","volume":"21","author":"Beutler","year":"1993","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/embo-reports\/kvd030","article-title":"Upwardly mobile proteins. The role of HMG proteins in chromatine structure, gene expression and neoplasia","volume":"1","author":"Bianchi","year":"2000","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0045","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.2922595","article-title":"Specific recognition of cruciform DNA by nuclear protein HMG1","volume":"243","author":"Bianchi","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0050","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","article-title":"Understanding RAGE, the receptor for advanced glycation end products","volume":"83","author":"Bierhaus","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0055","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1093\/emboj\/cdf692","article-title":"The DNA chaperone HMGB1 facilitates ACF\/CHRAC dependent nucleosome sliding","volume":"21","author":"Bonaldi","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0060","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1093\/emboj\/cdg516","article-title":"Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion","volume":"22","author":"Bonaldi","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10858-012-9671-0","article-title":"NMR characterization of the C-terminal tail of full-length RAGE in a membrane mimicking environment","volume":"54","author":"Borsi","year":"2012","journal-title":"J Biomol NMR"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0070","first-page":"1699","article-title":"Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues","volume":"143","author":"Brett","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2119\/2007-00107.Bruchfeld","volume":"14","author":"Bruchfeld","year":"2008","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/15257770701509602","article-title":"ODN-based drugs for targeting of extracellular proteins","volume":"26","author":"Bucci","year":"2007","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0085","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1128\/MCB.19.8.5237","article-title":"Regulation of DNA-dependent activities by the functional motifs of the high mobility group chromosomal proteins","volume":"19","author":"Bustin","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-4781(90)90092-G","article-title":"Structural features of the HMG chromosomal proteins and their genes","volume":"1049","author":"Bustin","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0095","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2353\/ajpath.2008.070969","article-title":"Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1","volume":"172","author":"Chorny","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0100","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1021\/bi7003735","article-title":"The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units","volume":"46","author":"Dattilo","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1189\/jlb.1008662","article-title":"Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis","volume":"86","author":"Dav\u00e9","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0115","doi-asserted-by":"crossref","first-page":"9899","DOI":"10.1016\/S0040-4020(99)00529-3","article-title":"Synthesis and characterization of new 3\u2032-3\u2032 linked oligodeoxyribonucleotides for alternate strand triple helix formation","volume":"55","author":"De Napoli","year":"1999","journal-title":"Tetrahedron"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0120","doi-asserted-by":"crossref","first-page":"9024","DOI":"10.1021\/jo970589t","article-title":"Synthesis and triple-helix formation by alternate strand recognition of oligonucleotides containing 3\u2032-3\u2032-phosphodiester bonds","volume":"62","author":"De Napoli","year":"1997","journal-title":"J Org Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0110","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1083\/jcb.152.6.1197","article-title":"The High Mobility Group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells","volume":"152","author":"Degryse","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/jm301248y","article-title":"Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo","volume":"56","author":"Du","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0130","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.4049\/jimmunol.174.12.7506","article-title":"Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products","volume":"174","author":"Dumitriu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0135","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/1078-0432.CCR-06-1953","article-title":"Masquerader: High mobility group box-1 and cancer","volume":"13","author":"Ellerman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0140","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","article-title":"The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway","volume":"3","author":"Gardella","year":"2002","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/2006-00108.Goldstein","article-title":"Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis","volume":"13","author":"Goldstein","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-3083.2008.02194.x","article-title":"Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice","volume":"69","author":"Gong","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/aps.2011.151","article-title":"Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1","volume":"33","author":"Gong","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0160","doi-asserted-by":"crossref","first-page":"915234","DOI":"10.1155\/2010\/915234","article-title":"The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal acidic tail","volume":"2010","author":"Gong","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0091-679X(08)60104-1","article-title":"The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins","volume":"16","author":"Goodwin","year":"1977","journal-title":"Methods Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1432-1033.1973.tb03026.x","article-title":"A new group of chromatin-associated proteins with a high content of acidic and basic amino acids","volume":"38","author":"Goodwin","year":"1973","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0175","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/COH.0b013e328349b089","article-title":"Natural killer cells, dendritic cells, and the alarmin high-mobility group box 1 protein: A dangerous trio in HIV-1 infection?","volume":"6","author":"Gougeon","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0180","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3748\/wjg.v18.i7.679","article-title":"Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway","volume":"18","author":"Gwak","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0185","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/SHK.0b013e3181b0ef7b","article-title":"In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models","volume":"33","author":"Hagiwara","year":"2010","journal-title":"Shock"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00540-006-0468-8","article-title":"Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury","volume":"21","author":"Hagiwara","year":"2007","journal-title":"J Anesth"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9000","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10753-008-9069-z","article-title":"A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1","volume":"31","author":"Hagiwara","year":"2008","journal-title":"Inflammation"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10059-011-0030-x","article-title":"RAGE: The beneficial and deleterious effects by diverse mechanisms of actions","volume":"31","author":"Han","year":"2011","journal-title":"Mol Cells"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0200","doi-asserted-by":"crossref","first-page":"16596","DOI":"10.1021\/bi00051a007","article-title":"Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three and four dimensional NMR spectroscopy","volume":"34","author":"Hardaman","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jss.2009.05.039","article-title":"Gabexate mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury","volume":"165","author":"Hidaka","year":"2011","journal-title":"J Surg Res"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0210","doi-asserted-by":"crossref","first-page":"19919","DOI":"10.1074\/jbc.274.28.19919","article-title":"Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-\u03baB require the cytoplasmic domain of the receptor but different downstream signaling pathways","volume":"274","author":"Huttunen","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0215","doi-asserted-by":"crossref","first-page":"16336","DOI":"10.1074\/jbc.M608467200","article-title":"Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils","volume":"282","author":"Ito","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/ard.2007.074484","volume":"67","author":"Jiang","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nbd.2011.12.056","article-title":"Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion","volume":"46","author":"Kim","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0230","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1523\/JNEUROSCI.3815-05.2006","article-title":"HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain","volume":"26","author":"Kim","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0235","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.str.2010.05.017","article-title":"Structural basis for ligand recognition and activation of RAGE","volume":"18","author":"Koch","year":"2010","journal-title":"Structure"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","article-title":"RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages","volume":"61","author":"Kokkola","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0245","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.11161","article-title":"Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity","volume":"48","author":"Kokkola","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/erc.12.13","article-title":"Novel pathways and therapies in experimental diabetic atherosclerosis","volume":"10","author":"Koulis","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0250","doi-asserted-by":"crossref","first-page":"e63073","DOI":"10.1371\/journal.pone.0063073","article-title":"Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein","volume":"8","author":"Kuroiwa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0255","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.fct.2012.03.003","article-title":"Inhibitory effects of lycopene on HMGB1-mediated pro-inflammatory responses in both cellular and animal models","volume":"50","author":"Lee","year":"2012","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0260","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1371\/journal.pone.0001153","article-title":"A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1","volume":"2","author":"Li","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF03402105","article-title":"Structural basis for the proinflammatory cytokine activity of high mobility group box 1","volume":"9","author":"Li","year":"2003","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0270","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.4049\/jimmunol.178.6.3856","article-title":"A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1","volume":"178","author":"Li","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0275","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2119\/molmed.2013.00064","article-title":"Carbenoxolone blocks endotoxin-induced PKR activation and HMGB1 release","volume":"19","author":"Li","year":"2013","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fimmu.2013.00068","article-title":"HMGB1: The central cytokine for all lymphoid cells","volume":"4","author":"Li","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0285","doi-asserted-by":"crossref","first-page":"30870","DOI":"10.1074\/jbc.273.47.30870","article-title":"Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells","volume":"273","author":"Li","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0290","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coph.2005.10.010","article-title":"Role of HMGB1 in cardiovascular diseases","volume":"6","author":"Li","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0295","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1074\/jbc.272.26.16498","article-title":"Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products","volume":"272","author":"Li","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0300","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/039463201202500413","article-title":"Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1\u2013RAGE axis","volume":"25","author":"Li","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0305","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3899\/jrheum.090663","article-title":"Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus","volume":"37","author":"Li","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0310","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1172\/JCI200418704","article-title":"Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response","volume":"113","author":"Liliensiek","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0315","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/aps.2013.8","article-title":"Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(\u2212\/\u2212) mice by downregulating the HMGB1\u2013RAGE axis","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0325","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/156652407783220697","article-title":"RAGE and RAGE ligands in cancer","volume":"7","author":"Logsdon","year":"2007","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0320","doi-asserted-by":"crossref","first-page":"R122","DOI":"10.1186\/cc6184","article-title":"Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection","volume":"11","author":"Lutterloh","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0330","first-page":"1403","article-title":"Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG\/PPG on and evaluation of its efficacy in the treatment of moderate to severe blepharitis","volume":"7","author":"Mencucci","year":"2013","journal-title":"Clin Ophtalmol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0335","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1039\/B915680A","article-title":"An alternative strategy to synthesize PNA and DNA magnetic conjugates forming nanoparticle assembly based on PNA\/DNA duplexes","volume":"6","author":"Milano","year":"2010","journal-title":"Mol BioSyst"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0350","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1021\/ol0603559","article-title":"Solid-phase synthesis of cyclic PNA and PNA\u2013DNA chimeras","volume":"8","author":"Moggio","year":"2006","journal-title":"Org Lett"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0345","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chembiol.2007.03.007","article-title":"Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities","volume":"14","author":"Mollica","year":"2007","journal-title":"Chem Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0355","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1432-1033.1989.tb15116.x","article-title":"Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions","volume":"185","author":"Mosevitsky","year":"1989","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0340","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1093\/emboj\/20.16.4337","article-title":"New EMBO members' review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal","volume":"20","author":"M\u00fcller","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0360","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1039\/c1mb05009e","article-title":"DNA-based strategies for blocking HMGB1 cytokine activity: Design, synthesis and preliminary in vitro\/in vivo assays of DNA and DNA-like duplexes","volume":"7","author":"Musumeci","year":"2011","journal-title":"Mol BioSyst"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0365","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2012.07.011","article-title":"Polyvalent nucleic acid aptamers and modulation of their activity: A focus on the thrombin binding aptamer","volume":"136","author":"Musumeci","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/bc200305t","article-title":"G-quadruplex-forming oligonucleotide conjugated to magnetic nanoparticles: synthesis, characterization, and enzymatic stability assays","volume":"23","author":"Musumeci","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0370","doi-asserted-by":"crossref","first-page":"12176","DOI":"10.1039\/c3ra41915k","article-title":"Hairpin ODN-based ligands as potential inhibitors of HMGB1 cytokine activity","volume":"3","author":"Musumeci","year":"2013","journal-title":"RSC Adv"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0375","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1097\/CCM.0b013e3181a55184","article-title":"Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia","volume":"37","author":"Nagato","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9015","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14728222.2011.575360","article-title":"HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation","volume":"15","author":"Nogueira-Machado","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0380","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.111.182592","article-title":"Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia\u2013reperfusion in rats","volume":"339","author":"Ogiku","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0385","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.neuropharm.2011.06.026","article-title":"HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats","volume":"61","author":"Ohnishi","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9020","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1016\/j.tetlet.2004.04.149","article-title":"Synthesis and characterization of a bunchy oligonucleotide forming a monomolecular parallel quadruplex structure in solution","volume":"45","author":"Oliviero","year":"2004","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0390","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/MCB.14.5.3376","article-title":"The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences","volume":"14","author":"Onate","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0395","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/sj.emboj.7601805","article-title":"Structural and functional insights into RAGE activation by multimeric S100B","volume":"26","author":"Ostendorp","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0400","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1189\/jlb.0908581","article-title":"Src family kinases are necessary for cell migration induced by extracellular HMGB1","volume":"86","author":"Palumbo","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1083\/jcb.200704015","article-title":"Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-\u03baB activation","volume":"179","author":"Palumbo","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1083\/jcb.200304135","volume":"164","author":"Palumbo","year":"2004","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0415","doi-asserted-by":"crossref","first-page":"40762","DOI":"10.1074\/jbc.M110.169276","article-title":"The 1.5\u00c5 crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding","volume":"285","author":"Park","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0420","doi-asserted-by":"crossref","first-page":"24730","DOI":"10.1074\/jbc.273.38.24730","article-title":"Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain","volume":"273","author":"Pasheva","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0425","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1101\/gad.7.8.1521","article-title":"The nonspecific DNA-binding and bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures","volume":"7","author":"Paull","year":"1993","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0430","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1126\/science.1566071","article-title":"Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin","volume":"256","author":"Pil","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0435","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar2440","article-title":"High-mobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease","volume":"10","author":"Pisetsky","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0440","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/nar\/21.15.3427","article-title":"Solution structure of a DNA-binding domain from HMG1","volume":"21","author":"Read","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0445","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1172\/JCI200319523","article-title":"The enigma of sepsis","volume":"112","author":"Riedemann","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0450","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1242\/dev.128.8.1265","article-title":"Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein HMGB2","volume":"128","author":"Ronfani","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0455","doi-asserted-by":"crossref","first-page":"37525","DOI":"10.1074\/jbc.M111.223438","article-title":"Solution structure of the soluble receptor for advanced glycation end products (sRAGE)","volume":"286","author":"S\u00e1rk\u00e1ny","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cell triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0465","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2119\/molmed.2010.00264","article-title":"Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models","volume":"17","author":"Schierbeck","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0470","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Schiraldi","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0480","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0475","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood-2004-10-3906","article-title":"NK\/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1","volume":"106","author":"Semino","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0485","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00005-012-0183-0","article-title":"The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy","volume":"60","author":"Smolarczyk","year":"2012","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0490","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-7-17","article-title":"RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation","volume":"7","author":"Sparvero","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0495","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.CCM.0000155991.88802.4D","article-title":"Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock","volume":"33","author":"Sunden-Cullberg","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9030","first-page":"685","article-title":"Microglial amyloid-\u03b21-40 phagocytosis dysfunction is caused by high-mobility group box protein-1: implications for the pathological progression of Alzheimer's disease","volume":"2012","author":"Takata","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0510","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1083\/jcb.200911078","article-title":"Endogenous HMGB1 regulates autophagy","volume":"190","author":"Tang","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0500","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1165\/rcmb.2008-0119OC","article-title":"Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function","volume":"41","author":"Tang","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0505","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","article-title":"High-mobility group box 1 and cancer","volume":"1799","author":"Tang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0515","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ni.2396","article-title":"Tumor immunity times out: TIM-3 and HMGB1","volume":"13","author":"Tang","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0520","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.intimp.2008.07.014","article-title":"PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia","volume":"8","author":"Tang","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0525","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1189\/jlb.0806540","article-title":"Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1","volume":"81","author":"Tang","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0530","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/bst0290395","article-title":"HMG1 and 2: Architectural DNA-binding proteins","volume":"29","author":"Thomas","year":"2001","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0535","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3892\/ol.2011.459","article-title":"High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues","volume":"3","author":"Todorova","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0540","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.biocel.2007.11.014","article-title":"HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail","volume":"40","author":"Topalova","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0550","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1021\/bi9004304","article-title":"Nucleosome binding properties and co-remodeling activities of native and in vivo acetylated HMGB-1 and HMGB-2 proteins","volume":"48","author":"Ugrinova","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0545","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.biocel.2009.01.010","article-title":"Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro","volume":"41","author":"Ugrinova","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0555","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.2011.02432.x","article-title":"High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus","volume":"270","author":"Urbonaviciute","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0560","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molimm.2012.10.037","article-title":"HMGB1 and leukocyte migration during trauma and sterile inflammation","volume":"55","author":"Venereau","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0565","doi-asserted-by":"crossref","first-page":"e66527","DOI":"10.1371\/journal.pone.0066527","article-title":"Dipotassium glycyrrhizate inhibits HMGB1-dependent inflammation and ameliorates colitis in mice","volume":"8","author":"Vitali","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0570","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11926-008-0054-1","article-title":"The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases","volume":"10","author":"Voll","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0575","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0014-5793(80)80453-4","article-title":"The primary structures of non-histone chromosomal proteins HMG1 and 2","volume":"122","author":"Walker","year":"1980","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0580","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0585","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2796.2003.01302.x","article-title":"Extracellular role of HMGB1 in inflammation and sepsis","volume":"255","author":"Wang","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0590","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbrc.2007.05.130","article-title":"The HMGB1 acidic tail regulates HMGB1 DNA binding specificity by a unique mechanism","volume":"360","author":"Wang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0595","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neulet.2010.01.030","article-title":"Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kB expression","volume":"471","author":"Wang","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0600","doi-asserted-by":"crossref","first-page":"R44","DOI":"10.1186\/cc12558","article-title":"Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response","volume":"17","author":"Wang","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0605","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/j.1460-2075.1993.tb05776.x","article-title":"Structure of the HMG box motif in the B-domain of HMG1","volume":"12","author":"Weir","year":"1993","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0610","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1189\/jlb.1212662","article-title":"The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis","volume":"93","author":"Yang","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0615","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2119\/2006-00010.Yang","article-title":"Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock","volume":"12","author":"Yang","year":"2006","journal-title":"Mol Med"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0620","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1073\/pnas.2434651100","article-title":"Reversing established sepsis with antagonists of endogenous high-mobility group box 1","volume":"1","author":"Yang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0625","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/nar\/20.13.3516","article-title":"Nucleotide sequence of a mouse cDNA encoding the nonhistonne chromosomal high mobility group protein-1 (HMG1)","volume":"20","author":"Yotov","year":"1992","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0630","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.4049\/jimmunol.177.11.7889","article-title":"Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion","volume":"177","author":"Youn","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0635","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/aps.2012.112","article-title":"Glycyrrhizin protects rat heart against ischemia\u2013reperfusion injury through blockade of HMGB1-dependent phospho-JNK\/Bax pathway","volume":"33","author":"Zhai","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0640","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bcp.2012.09.015","article-title":"Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake","volume":"84","author":"Zhang","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb0645","first-page":"1511","article-title":"Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1\u2013RAGE and Akt pathways in vitro and in vivo","volume":"27","author":"Zhang","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pharmthera.2013.11.001_bb9035","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/ar3747","article-title":"Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis","volume":"14","author":"Zickert","year":"2012","journal-title":"Arthritis Res Ther"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813002192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T10:02:53Z","timestamp":1688637773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813002192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0163725813002192"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}